These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
767 related articles for article (PubMed ID: 27113415)
1. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415 [TBL] [Abstract][Full Text] [Related]
2. Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. Curtis JR; Xie F; Yang S; Bernatsky S; Chen L; Yun H; Winthrop K Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1249-1254. PubMed ID: 30295428 [TBL] [Abstract][Full Text] [Related]
3. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Xie F; Yun H; Bernatsky S; Curtis JR Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279 [TBL] [Abstract][Full Text] [Related]
4. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Winthrop KL; Yamanaka H; Valdez H; Mortensen E; Chew R; Krishnaswami S; Kawabata T; Riese R Arthritis Rheumatol; 2014 Oct; 66(10):2675-84. PubMed ID: 24943354 [TBL] [Abstract][Full Text] [Related]
5. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials. Lee YH; Bae SC Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536 [TBL] [Abstract][Full Text] [Related]
7. Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Winthrop KL; Curtis JR; Lindsey S; Tanaka Y; Yamaoka K; Valdez H; Hirose T; Nduaka CI; Wang L; Mendelsohn AM; Fan H; Chen C; Bananis E Arthritis Rheumatol; 2017 Oct; 69(10):1960-1968. PubMed ID: 28845604 [TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566 [TBL] [Abstract][Full Text] [Related]
9. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs. Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115 [TBL] [Abstract][Full Text] [Related]
10. Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Winthrop KL; Melmed GY; Vermeire S; Long MD; Chan G; Pedersen RD; Lawendy N; Thorpe AJ; Nduaka CI; Su C Inflamm Bowel Dis; 2018 Sep; 24(10):2258-2265. PubMed ID: 29850873 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769 [TBL] [Abstract][Full Text] [Related]
12. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR Arthritis Care Res (Hoboken); 2015 May; 67(5):731-6. PubMed ID: 25201241 [TBL] [Abstract][Full Text] [Related]
13. A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population. Kivitz AJ; Cohen S; Keystone E; van Vollenhoven RF; Haraoui B; Kaine J; Fan H; Connell CA; Bananis E; Takiya L; Fleischmann R Semin Arthritis Rheum; 2018 Dec; 48(3):406-415. PubMed ID: 30177460 [TBL] [Abstract][Full Text] [Related]
14. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors. Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419 [TBL] [Abstract][Full Text] [Related]
15. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database. Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330 [TBL] [Abstract][Full Text] [Related]
16. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964 [TBL] [Abstract][Full Text] [Related]
17. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. Maneiro JR; Souto A; Gomez-Reino JJ Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845 [TBL] [Abstract][Full Text] [Related]
18. [Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis]. Yamaoka K Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):181-9. PubMed ID: 27320933 [TBL] [Abstract][Full Text] [Related]
19. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Bechman K; Subesinghe S; Norton S; Atzeni F; Galli M; Cope AP; Winthrop KL; Galloway JB Rheumatology (Oxford); 2019 Oct; 58(10):1755-1766. PubMed ID: 30982883 [TBL] [Abstract][Full Text] [Related]
20. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study. Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]